

DMB

Display Date	6-17-99
Publication Date	6-18-99
Certifier	J. McDonald

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 99N-1174]

**Dietary Supplements; Center for Food Safety and Applied Nutrition Strategy; Public Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

---

**SUMMARY:** The Food and Drug Administration (FDA) is announcing a second public meeting to solicit comments that will assist the Center for Food Safety and Applied Nutrition (CFSAN) to develop an overall strategy for achieving effective regulation of dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). This meeting is intended to give the public an opportunity to comment on the development of the strategy.

**DATES:** The public meeting will be held on July 20, 1999, from 9 a.m. to 5 p.m. Submit written comments by August 20, 1999.

**ADDRESSES:** The public meeting will be held at the Oakland Federal Bldg., third fl. auditorium, north tower, 1301 Clay St., Oakland, CA.

**FOR FURTHER INFORMATION CONTACT:** Janet B. McDonald, Office of Regulatory Affairs (HFR-PA-145), Food and Drug Administration, 1431 Harbor Bay Pkwy., Alameda, CA 94502-7070, 510-337-6845, FAX 510-337-6708, "e-mail [jmcdonal@ora.fda.gov](mailto:jmcdonal@ora.fda.gov)."

**SUPPLEMENTARY INFORMATION:**

**I. Introduction**

This public meeting is the second of two meetings to seek stakeholder comments on the development of an overall strategy for achieving effective regulation of dietary supplements under

the Federal Food, Drug, and Cosmetic Act, as amended by DSHEA. The first meeting was held on June 8, 1999, in Washington, DC. These two meetings build upon themes that emerged from a broader stakeholder meeting sponsored by CFSAN in June 1998. That meeting addressed the nonfood safety initiative programs that are managed by CFSAN and identified some basic themes including: (1) The need to maintain a credible FDA program, including compliance, enforcement, and consumer outreach activities that will help ensure consumer confidence in FDA regulated products; (2) the need to maintain a solid, science based program staffed with highly qualified scientists; and (3) the recognition that FDA's assistance to consumers and the regulated industry is important.

## **II. Registration and Requests for Oral Presentations**

If you would like to attend the public meeting, you must register with the contact person (address above) by July 9, 1999, by providing your: name, title, business affiliation, address, telephone, and fax number. To expedite processing, registration information may also be faxed to 510-337-6708. If you need special accommodations due to disability, please inform the contact person when you register.

If you wish to make an oral presentation during the meeting, you must inform the contact person of that desire when you register to attend and submit: (1) A brief written statement of the general nature of the evidence or arguments that you wish to present, (2) the names and addresses of the persons who will give the presentation, and (3) the approximate length of time that you are requesting for your presentation. Depending on the number of people who register to make presentations, we may have to limit the time allotted for each presentation.

## **III. CFSAN's 1999 Program Priorities Document**

The meeting announced in this notice, as well as the meeting that took place on June 8, 1999, in Washington, DC, are in response to CFSAN's 1999 Program Priorities document that calls for the development of an overall dietary supplement strategy in conjunction with other agency

units and stakeholders. A copy of the priorities document is available on the Internet on FDA's Website at "<http://vm.cfsan.fda.gov/~dms/cfsan199.html>".

The priorities document states that the overall strategy should address all elements of the dietary supplement program including: (1) Boundaries between dietary supplements and conventional foods, between dietary supplements and drugs, and between dietary supplements and cosmetic products; (2) claims; (3) good manufacturing practices; (4) adverse event reporting; (5) laboratory capability; (6) research needs; (7) enforcement; and (8) resource needs. FDA's objective in developing this strategy is to ensure consumer access to safe dietary supplements that are truthfully and not misleadingly labeled. FDA intends to develop this strategy by following a process of openness, flexibility, efficiency, and commitment to public health.

FDA has identified four criteria for priority ranking the tasks encompassed in the strategy. These criteria are: (1) Enhancement of consumer safety, (2) development of health-related product labeling regulation, (3) improvement in efficiency of operation, and (4) closure on unresolved regulatory issues.

This meeting also addresses activity undertaken by the agency to solicit comments in accordance with section 406(b) of the Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115) (21 U.S.C. 393(b)).

#### **IV. Agenda and Goals**

To help focus comments for the July 20, 1999, meeting, FDA requests that oral and written input regarding an overall strategy for achieving effective regulation of dietary supplements address the following questions:

1. In addition to ensuring consumer access to safe dietary supplements that are truthfully and not misleadingly labeled, are there other objectives that an overall dietary supplement strategy should include?

2. Are the criteria for prioritizing the tasks within the supplement strategy appropriate? Which specific tasks should FDA undertake first?

3. What factors should FDA consider in determining how best to implement a task (i.e., use of regulations, guidance, etc.)?

4. What tasks should be included under the various dietary supplement program elements in the CFSAN 1999 Program Priorities document?

5. Are there current safety, labeling, or other marketplace issues that FDA should address quickly through enforcement actions to ensure, for example, that consumers have confidence that the products on the market are safe, truthfull, and not misleadingly labeled?

6. Toward what type or area of research on dietary supplements should FDA allocate its research resources?

7. Given FDA's limited resources, what mechanisms are available, or should be developed, to leverage FDA's resources to meet effectively the objective of the strategy?

## **V. Comments**


Interested persons may, on or before August 20, 1999, submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. You may also send comments to the Dockets Management Branch via e-mail to "FDA Dockets@bangate.fda.gov" or via the FDA Website "<http://www.fda.gov>". You should annotate and organize your comments to identify the specific issues to which they refer. You must submit two copies of comments, identified with the docket number found in brackets in the heading of this document, except that you may submit one copy if you are an individual. You may review received comments in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.


## **VI. Transcripts**

You may request transcripts of the meeting in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. You may also

examine the transcript of the meeting at the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday, as well as on the FDA Website "http://www.fda.gov". "http://vm.cfsan.fda.gov/dms/cfsan199.html".

Dated: 6-11-99  
June 11, 1999

  
\_\_\_\_\_  
Margaret M. Dotzel  
Acting Associate Commissioner for  
Policy Coordination

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL  


[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

BILLING CODE 4160-01-F